Camonsertib
Camonsertib is an investigational new drug that is being evaluated for the treatment of cancer.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Camonsertib is an investigational new drug that is being evaluated for the treatment of cancer. It is a selective oral small molecule inhibitor of ATR (Ataxia telangiectasia and Rad3 related), developed by Repare Therapeutics.
This drug targets tumors with specific genetic alterations that create vulnerabilities in DNA damage response (DDR) pathways, particularly those with ATM or BRCA1/BRCA2 mutations. It is currently in Phase 2 clinical trials both as a monotherapy and in combination with other agents, including PARP inhibitors, gemcitabine, and lunresertib.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1359354352 under CC BY-SA 4.0; modifications have been made.